Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study to reduce chemo in HER2+ breast cancer withdrawn before start

NCT ID NCT04419181

Terminated Disease control Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study aimed to see if giving less chemotherapy before surgery, followed by targeted therapy, could work well for women with early-stage HER2-positive breast cancer. It planned to enroll women with tumors at least 2 cm or lymph node involvement. However, the study was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Trastuzumab emtansine
What this could lead to
If successful, this approach could show that some patients with early HER2+ breast cancer can safely receive less chemotherapy, reducing side effects while maintaining good outcomes.
What could go wrong
The study was withdrawn before enrolling any participants, so no data was collected. The approach may not be effective or safe in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE BREAST CANCER

Contacts and locations

Locations

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.